Renewal Strategy: Prepare 90 Days Before Expiry

Renewal preparation begins at 90 days before policy expiration. The reason is not arbitrary. The data the incumbent carriers need to renew, the operational updates the underwriting conversation requires, and the time required to market specific lines to alternative carriers if a structural decision warrants it, all sit on a timeline that pushes back into the third month before renewal.

Companies that begin renewal preparation at 30 days are not buying insurance. They are accepting whatever the incumbent carriers offer at the deadline. For life sciences companies with regulated exposure, specialty markets, and stage-dependent program structures, that posture leaves coverage and price decisions on the table.

This walks through the renewal cycle most brokers run, why 90 days is the operational window, what specific work should happen at each stage, the life sciences items that need to be in the conversation, and how to evaluate whether the renewal is the right moment to change brokers.

The Renewal Cycle Most Brokers Run

The standard commercial renewal cycle has four phases.

Phase 1: Data collection (90 to 60 days out). Loss runs are ordered from incumbent carriers. Current applications and exposure schedules are updated. Operational changes are documented (headcount, revenue, regulatory standing, R&D milestones, product pipeline). For life sciences, this is the phase that takes longest because the volume of operational documentation is meaningful.

Phase 2: Strategy and marketing decisions (60 to 45 days out). The broker meets with the company to review the prior year’s program, identify any structural changes warranted by operational shifts, and decide which lines to market. The decision is line-by-line, not blanket. Some lines stay with the incumbent for relationship and loss-history reasons; others go to market because appetite or pricing has shifted.

Phase 3: Submission and underwriter engagement (45 to 15 days out). Submissions go to selected markets. Underwriter questions get answered. Quotes come back. The broker negotiates wording, sub-limits, and price.

Phase 4: Binding and documentation (15 to 0 days). Final decisions are made, binders are issued, certificates are generated, and the program is in place at renewal.

This is the cycle that operates cleanly when the work starts at 90 days. Compress it to 60 days and quality drops. Compress to 30 days and the renewal effectively becomes a hold-cover decision with the incumbent.

Why 90 Days Is the Real Window

Three operational realities make 90 days the right starting point for life sciences renewals.

Loss runs take time to assemble. Carriers issue loss runs within 30 days typically, but for a program with five to ten lines across multiple carriers, the actual aggregation takes a full month from the request. Loss runs delivered at day 60 with errors or omissions push the marketing window into a compressed back-half.

Specialty markets work on longer underwriting cycles. Life sciences products liability, D&O for regulated companies, cyber for HIPAA-regulated entities, and clinical trial liability all run on specialty markets with longer underwriting cycles than commodity commercial lines. 60 days is the minimum for proper engagement; 90 days produces better outcomes.

Operational updates require internal coordination. The information the underwriting conversation requires is scattered across regulatory affairs, finance, R&D, legal, and operations. Gathering it under time pressure produces incomplete or inaccurate submissions. Gathering it methodically with 90 days produces a high-quality submission.

Day 90 to Day 60: Data Collection and Internal Alignment

The first 30 days of the 90-day window are about getting the data right.

Order loss runs. Request from the incumbent broker or directly from carriers, with a specified return date (typically 21 to 30 days). Recently bound policies may not have a full loss run yet but should produce a no-loss letter.

Update operational data. Current revenue, current headcount, current state and international footprint, current product mix, current customer mix. The data set should be the same one the company would use in a fundraising or M&A diligence package.

Catalog regulatory standing. Any FDA submissions and clearances during the year. Any Warning Letters, 483s, or untitled letters received or closed. Any OCR matters open or closed. Any CAP or CLIA inspection findings. Any state regulatory matters. The list should be current as of the data request.

Inventory clinical trial activity. Active protocols, IRBs of record, sites involved, sponsor obligations, and any protocol amendments during the year. For sponsors and CROs, this drives the clinical trial liability and the broader program structure.

Catalog BAA inventory. For HIPAA-regulated entities, the current BAA inventory with any new BAAs added during the year, any business associate departures, and any breach matters reportable under the breach notification framework.

Document operational changes. New product launches, new geographies, new partnerships, new contract manufacturers, new SaMD modifications, new lab testing menu additions. Underwriters price operational change; the change should be visible in the submission.

Identify the changes that drive the renewal narrative. What is meaningfully different about the company this year versus last year. Specialty underwriters read the renewal application for the story; the company should know what story it is telling before the broker drafts it.

Day 60 to Day 30: Strategy and Marketing Decisions

The second 30-day window is about deciding what to do with the data.

Review prior-year placement decisions. What worked. What did not. Where coverage was thin. Where the company paid for coverage it did not value. The retrospective sets up the prospective.

Make line-by-line marketing decisions. Not every line is re-marketed every year. The decision criteria typically include: incumbent carrier’s loss ratio with the company, recent appetite shifts in the broader market, structural reasons to consider alternatives (sub-limit changes, wording deficiencies, service issues), and the cost of switching versus the value of the change.

For lines being re-marketed, identify target markets. The broker should be able to articulate which specialty markets are being approached and why. A blind marketing exercise that goes to every carrier in the segment is operationally wasteful and damages broker-carrier relationships.

Prepare narrative responses to expected underwriter questions. Prior-year submissions usually generate underwriter follow-ups. The renewal should anticipate those and include the narrative in the submission rather than waiting for the questions to come back.

Coordinate with the company’s other advisors. Legal counsel on regulatory matters that affect underwriting. Auditor on any financial statement items that surfaced in the year. Outside compliance counsel on any matter that affects the application.

Decide on the marketing depth. A full re-marketing of every line is appropriate when the program is structurally underperforming or the company has materially changed. A targeted re-marketing of 2 to 3 lines is appropriate when most of the program is performing but specific structural changes are warranted. Full hold-cover (no marketing at all) is appropriate when the program is structurally sound and the operational profile has not materially changed.

Day 30 to Renewal: Submission, Negotiation, and Binding

The final 30 days are about execution.

Issue submissions to selected markets. Complete, well-organized submissions with all attachments in place. Underwriters’ first read of the submission shapes the placement; quality matters.

Manage underwriter Q&A. Most underwriters generate follow-up questions within a week of receiving a submission. Fast, complete responses keep the quote timeline on track.

Negotiate wording and sub-limits, not just price. A renewal that focuses only on premium and ignores wording produces a placement that may look attractive at binding and underperform at claim.

Compare quotes against the prior year and against marketed alternatives. The comparison should be on structure first, price second. A 10% premium reduction with a sub-limit cut or an exclusion added is often a worse outcome than holding the prior structure at flat pricing.

Make the binding decision with the company’s stakeholders. For life sciences companies, this is typically a CFO + COO + GC review. The decision should be informed by the year’s operational priorities and any anticipated transactions or fundraising milestones.

Bind and document. Binders, certificates, and any required filings should be in place at renewal. Late binding produces day-after-expiration gaps that can produce uninsured exposure if a claim arises in the window.

Life Sciences-Specific Items the Renewal Should Address

Several items show up only in life sciences renewals and require specific attention.

Products liability sub-limit review. Indication scope, distribution geography, distributor AI grants, and international coverage extensions. A products program that was sized appropriately at the prior renewal may not be sized appropriately if commercial scale has grown.

D&O tower review for stage-dependent companies. Companies that have raised a new round, hired new directors, or expanded internationally should review the tower structure rather than holding the prior year’s limits.

Cyber and HIPAA program review. Particularly under the OCR Risk Analysis Initiative, the documentation that supports the cyber and HIPAA application has tightened. The renewal should reflect any improvements in the risk analysis posture and any breach notification activity during the year.

Clinical trial liability scope changes. Active protocols, indications, and geographies as of the renewal date. The placement should reflect current activity, not the prior year’s profile.

EPLI program scaling. Headcount growth, state footprint expansion, and any open employment matters affect EPLI placement. Companies crossing material headcount thresholds may have outgrown the prior year’s structure.

Tech E&O coordination for SaMD or HealthTech. Where the company has expanded its software or service offerings, the Tech E&O and products coordination should be reviewed against the current product surface area.

What Sophisticated Buyers Push For

A renewal is also a leverage moment. Sophisticated life sciences buyers use the renewal to push on specific items.

Wording improvements over premium reductions. Tighter wording on additional insureds, vendor coverage, regulatory defense sub-limits, and notification cost provisions is durable value. A premium reduction without wording improvement is a one-year benefit.

Sub-limit expansions where the prior year was thin. Specific sub-limits that constrained placement value in the prior year (regulatory defense, notification, business interruption inside recall, breach response inside cyber) should be expanded if the renewal market supports it.

Better claim handling commitments. Carriers vary in claim handling responsiveness. Renewal is a leverage moment to push for designated claim contacts, faster acknowledgment timelines, and clearer escalation pathways.

More granular reporting. Carriers can produce loss reports, exposure summaries, and program dashboards that improve internal governance. The renewal is when these get negotiated.

Reduced retentions where loss history supports it. Companies with strong loss experience can negotiate retention reductions or aggregate retention caps that improve cash predictability.

When a Broker Change Is Justified

The renewal is also the structural moment to evaluate whether the incumbent broker is the right placement partner for the next year. The decision should be made on substance, not on premium quote competition.

Specialty fit. Does the incumbent have substantive engagement with the life sciences segment as a specialty practice? Are submissions reading like the broker understands the company’s regulatory profile, or are they reading like a generic commercial submission with FDA and HIPAA inserted? The difference shows up in placement outcomes.

Market access. Does the broker have appointment relationships with the specialty markets that write the company’s segment? Generalist brokers often go to a narrow subset of markets and rely on wholesalers for the rest. Specialty brokers carry direct appointments with the markets that price the placement.

Renewal preparation cadence. Does the broker start the renewal at 90 days, or at 45 days when the company prompts them? Renewal cadence is a leading indicator of how the broker will perform in a placement that requires real engagement.

Wording-level engagement. Does the broker negotiate wording, or only price? A broker who runs renewals on price alone is producing a degraded program over time.

Claim handling support. When a claim arises, does the broker advocate effectively with the carrier? Claim handling is where broker quality is most visible.

If any of these are not where they should be, the renewal is the natural moment to evaluate a change. The broker-of-record change process takes 30 to 45 days to execute cleanly, so the decision should be made at the 60-day window if a change is being considered.

A Note on Placement

MedTech Coverage works with life sciences companies on renewal preparation, broker-of-record transitions, and program structural reviews across the digital health, medical device, and clinical lab segments. Coverage is placed through Tower Street Insurance’s appointments with the specialty markets that underwrite the segment.

If a renewal is approaching at 90, 60, or 30 days, or if a broker change is being evaluated against the upcoming renewal cycle, a structured coverage review produces a working document calibrated to the company’s current operational profile, regulatory standing, and the placement decisions that should be made before binding.